4-(2-溴-5-氟苯氧基)哌啶盐酸盐 | 916971-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-溴-5-氟苯氧基)哌啶盐酸盐
• 英文名称: 4-(2-bromo-5-fluorophenoxy)piperidine
• CAS: 916971-27-2
• 化学式: C₁₁H₁₃BrFNO
• 分子量: 274.133
• InChiKey: WAJQDKIRJHQUAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-溴-5-氟苯氧基)哌啶盐酸盐 在 甲酸 、 sodium azide 、 三乙胺 、 zinc(II) oxide 、 sodium hydroxide 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 水 为溶剂， 反应 32.58h， 生成 2H-四唑乙酸,5-[3-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-5-异恶唑]-
  参考文献：
  名称：

  Development of a Practical Synthesis of Stearoyl-CoA Desaturase (SCD1) Inhibitor MK-8245

  摘要：

  A practical kilogram scale chromatography-free synthesis of stearoyl-CoA desaturase 1 (SCD1) inhibitor MK-8245 is described. The key features of this sequence include an efficient addition elimination reaction of a piperidine fragment with a 3-bromoisoxaline followed by an iodine-mediated oxidation to the corresponding isoxazole. The development of a safe and scalable tetrazole formation protocol is also presented.

  DOI：

  10.1021/op200186d
• 作为产物：
  描述：

  4-(2-溴-5-氟苯氧基)哌啶盐酸盐 在 sodium hydroxide 作用下， 以 水 为溶剂， 生成 4-(2-溴-5-氟苯氧基)哌啶盐酸盐
  参考文献：
  名称：

  [EN] BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  [FR] COMPOSÉS HÉTÉROAROMATIQUES BICYCLIQUES EN TANT QU'INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE

  摘要：

  结构式I的双环杂芳化合物是硬脂酰辅酶A 9-脱饱和酶（SCD）的抑制剂。本发明的化合物对预防和治疗与异常脂质合成和代谢相关的疾病有用，包括心血管疾病；动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；肝脂肪变性；以及非酒精性脂肪肝。

  公开号：

  WO2009012573A1

文献信息

• Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
  申请人：Leblanc Yves

  公开号：US20080182838A1

  公开（公告）日：2008-07-31

  Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式I的氮杂环烷衍生物相对于其他已知的硬脂酰辅酶A去饱和酶(SCD1)具有选择性抑制作用。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；以及肝脂肪变性。
• Regioselective SNAr reactions of substituted difluorobenzene derivatives: practical synthesis of fluoroaryl ethers and substituted resorcinols
  作者：Stéphane G. Ouellet、Anna Bernardi、Remy Angelaud、Paul D. O’Shea

  DOI：10.1016/j.tetlet.2009.03.204

  日期：2009.7

  In this Letter, we describe a practical and highly selective method for the preparation of fluoroaryl ethers and differentially substituted resorcinol derivatives. This synthetic strategy relies on a selective SNAr of substituted difluorobenzene derivatives with various alcohols.

  在这封信中，我们描述了一种实用且高度选择性的方法，用于制备氟代芳基醚和差异取代的间苯二酚衍生物。该合成策略依赖于取代的二氟苯衍生物与各种醇的选择性S N Ar。
• Azacycloalkane Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
  申请人：Ramtohul Yeemam K.

  公开号：US20090318476A1

  公开（公告）日：2009-12-24

  Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis. Formula (I).

  结构式I的氮杂环烷衍生物是选择性抑制硬脂酰辅酶A-Δ9-去饱和酶（SCD1）的化合物，相对于其他已知的硬脂酰辅酶A去饱和酶。本发明的化合物可用于预防和治疗与异常脂质合成和代谢有关的疾病，包括心血管疾病，如动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。结构式（I）。
• AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Oballa Renata M.

  公开号：US20100004245A1

  公开（公告）日：2010-01-07

  Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的Azacycloalkane衍生物是选择性抑制stearoyl-coenzyme A delta-9去饱和酶（SCD1）相对于其他已知的stearoyl-coenzyme A去饱和酶的化合物。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。
• Cyclic Derivatives as Inhibitors of Stearoyl-Coenzyme a Delta-9 Desaturase
  申请人：Leblanc Yves

  公开号：US20100004287A1

  公开（公告）日：2010-01-07

  Cyclic amine derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

  结构式（I）的环状胺衍生物是选择性抑制硬脂酰辅酶A Δ-9去饱和酶（SCD1）相对于其他已知硬脂酰辅酶A去饱和酶的化合物。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病，包括心血管疾病；动脉粥样硬化；肥胖症；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗和肝脂肪变性。